Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?

Garg M, Royce SG, Tikellis C, Shallue C, Batu D, Velkoska E, Burrell LM, Patel SK, Beswick L, Jackson A, Britto K, Lukies M, Sluka P, Wardan H, Hirokawa Y, Tan CW, Faux M, Burgess AW, Hosking P, Monagle S, Thomas M, Gibson PR, Lubel J.

Gut. 2019 Aug 13. pii: gutjnl-2019-318512. doi: 10.1136/gutjnl-2019-318512. [Epub ahead of print]

PMID:
31409604
2.

Recent advances in the enzymatic synthesis of sugar-nucleotides using nucleotidylyltransferases and glycosyltransferases.

Ahmadipour S, Beswick L, Miller GJ.

Carbohydr Res. 2018 Nov;469:38-47. doi: 10.1016/j.carres.2018.09.002. Epub 2018 Sep 14. No abstract available.

PMID:
30265902
3.

Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study.

Motaganahalli S, Beswick L, Con D, van Langenberg DR.

Intern Med J. 2019 Jan;49(1):94-100. doi: 10.1111/imj.14027.

PMID:
29962008
4.

Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.

Vasudevan A, Beswick L, Friedman AB, Moltzen A, Haridy J, Raghunath A, Sparrow M, van Langenberg D.

Dig Liver Dis. 2018 Jul;50(7):682-688. doi: 10.1016/j.dld.2018.02.001. Epub 2018 Feb 10.

PMID:
29525182
5.

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study.

Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR.

J Crohns Colitis. 2018 Feb 28;12(3):289-297. doi: 10.1093/ecco-jcc/jjx146.

PMID:
29121178
6.

Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.

Ward MG, Thwaites PA, Beswick L, Hogg J, Rosella G, Van Langenberg D, Reynolds J, Gibson PR, Sparrow MP.

Aliment Pharmacol Ther. 2017 Apr;45(8):1135-1145. doi: 10.1111/apt.13992. Epub 2017 Feb 27.

7.

Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis.

Beswick L, Ye B, van Langenberg DR.

Inflamm Bowel Dis. 2016 Dec;22(12):2966-2976. Review.

PMID:
27763950
8.

Conflict of interest: real and perceived--a more mature consideration is needed.

Andrews JM, Costello SP, Agarwal AK, Bampton P, Beswick L, Connor S, Ghaly S, O'Connor S, Pudipeddi A, Sechi A, Sparrow M, Walsh AJ.

Intern Med J. 2016 Mar;46(3):377-9. doi: 10.1111/imj.12989. No abstract available.

PMID:
26968604
9.

Never underestimate inflammatory bowel disease: High prevalence rates and confirmation of high incidence rates in Australia.

Studd C, Cameron G, Beswick L, Knight R, Hair C, McNeil J, Desmond P, Wilson J, Connell W, Bell S.

J Gastroenterol Hepatol. 2016 Jan;31(1):81-6. doi: 10.1111/jgh.13050.

PMID:
26222770
10.

Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients.

Costello SP, Ghaly S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, O'Connor S, Connor SJ, Sparrow MP, Bampton P, Walsh AJ, Andrews JM; Australian Inflammatory Bowel Disease Association (AIBDA).

Intern Med J. 2015 Jun;45(6):659-66. doi: 10.1111/imj.12732.

PMID:
25732268
11.
12.

Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response.

Ghaly S, Costello S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, Antoniades S, Headon B, Connor S, Lawrance IC, Sparrow M, Walsh AJ, Andrews JM; AIBDA.

Intern Med J. 2015 Feb;45(2):170-7. doi: 10.1111/imj.12621.

PMID:
25370691
13.

The role of thiopurine metabolite monitoring in inflammatory bowel disease.

Beswick L, Friedman AB, Sparrow MP.

Expert Rev Gastroenterol Hepatol. 2014 May;8(4):383-92. doi: 10.1586/17474124.2014.894878. Epub 2014 Mar 31. Review.

PMID:
24684593
14.

Letter: Azathioprine-induced pancreatitis and subsequent tolerance of mercaptopurine.

Beswick L, Dowling D.

Aliment Pharmacol Ther. 2014 Feb;39(4):440. doi: 10.1111/apt.12584. No abstract available.

15.

Hepatitis C virus heterogeneity: lipoprotein and immunoglobulin binding and clinical status.

Adler NR, Biddle M, Beswick L, Hair C, Allen B, Graves S, Islam A, Watson JP.

J Clin Exp Hepatol. 2013 Dec;3(4):362-3. doi: 10.1016/j.jceh.2013.08.010. Epub 2013 Sep 5. No abstract available.

16.

Letter: successful mercaptopurine therapy after azathioprine-related pancreatitis in patients with IBD.

Beswick L, Hair CS, Dowling D.

Aliment Pharmacol Ther. 2013 Jan;37(1):162. doi: 10.1111/apt.12097. No abstract available.

17.

Neurotrophin-3 prevents the proximal accumulation of neurofilament proteins in sensory neurons of streptozocin-induced diabetic rats.

Sayers NM, Beswick LJ, Middlemas A, Calcutt NA, Mizisin AP, Tomlinson DR, Fernyhough P.

Diabetes. 2003 Sep;52(9):2372-80.

Supplemental Content

Loading ...
Support Center